DK3097925T3 - Farmaceutisk sammensætning - Google Patents

Farmaceutisk sammensætning Download PDF

Info

Publication number
DK3097925T3
DK3097925T3 DK16179161.1T DK16179161T DK3097925T3 DK 3097925 T3 DK3097925 T3 DK 3097925T3 DK 16179161 T DK16179161 T DK 16179161T DK 3097925 T3 DK3097925 T3 DK 3097925T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
DK16179161.1T
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Leuven Fred Van
Bosch Maria Pihlgren
Original Assignee
Ac Immune Sa
Katholieke Univ Leuven Ku Leuven Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3097925(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Katholieke Univ Leuven Ku Leuven Research & Development filed Critical Ac Immune Sa
Application granted granted Critical
Publication of DK3097925T3 publication Critical patent/DK3097925T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
DK16179161.1T 2009-04-03 2010-04-01 Farmaceutisk sammensætning DK3097925T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157303 2009-04-03
EP10713172.4A EP2413957B1 (en) 2009-04-03 2010-04-01 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK3097925T3 true DK3097925T3 (da) 2019-08-05

Family

ID=42269736

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10713172.4T DK2413957T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning
DK16179161.1T DK3097925T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10713172.4T DK2413957T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning

Country Status (28)

Country Link
US (3) US8647631B2 (da)
EP (2) EP2413957B1 (da)
JP (2) JP5810076B2 (da)
KR (2) KR20150041203A (da)
CN (2) CN105524160B (da)
AU (1) AU2010233856B2 (da)
BR (1) BRPI1015088B1 (da)
CA (1) CA2757345C (da)
CL (2) CL2011002457A1 (da)
CO (1) CO6390113A2 (da)
CR (1) CR20110509A (da)
DK (2) DK2413957T3 (da)
EC (1) ECSP11011367A (da)
ES (2) ES2738623T3 (da)
HU (2) HUE044981T2 (da)
IL (1) IL215451A (da)
MA (1) MA34120B1 (da)
MX (1) MX2011010353A (da)
MY (1) MY171300A (da)
NZ (1) NZ595856A (da)
PL (2) PL3097925T3 (da)
PT (2) PT2413957T (da)
RU (1) RU2582916C2 (da)
SG (1) SG175037A1 (da)
SI (2) SI2413957T1 (da)
UA (1) UA107571C2 (da)
WO (1) WO2010115843A2 (da)
ZA (1) ZA201107776B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
WO2012020124A1 (en) * 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
MY164376A (en) * 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014150877A2 (en) * 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン,インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) * 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對tau之抗體及其用途
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
MX2019006330A (es) 2016-12-07 2019-09-26 Genentech Inc Anticuerpos anti-tau y metodos de uso.
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
WO2020072677A1 (en) 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
MY206596A (en) * 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) * 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
PT1036092E (pt) * 1997-12-03 2005-09-30 Biogen Inc Compos~icoes e metodos de proteinas hidrofobicamente modificadas
JP2004503747A (ja) 2000-07-11 2004-02-05 モレキュラー ジェリアトリクス コーポレイション 結合物質の同定するための試薬と方法
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
CN101965365A (zh) 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用

Also Published As

Publication number Publication date
CN102946899B (zh) 2016-01-20
RU2582916C2 (ru) 2016-04-27
JP2015214559A (ja) 2015-12-03
US8647631B2 (en) 2014-02-11
PT2413957T (pt) 2016-09-30
ZA201107776B (en) 2014-03-26
MX2011010353A (es) 2011-12-06
BRPI1015088A2 (pt) 2016-06-28
SG175037A1 (en) 2011-11-28
CN105524160B (zh) 2019-07-19
WO2010115843A2 (en) 2010-10-14
WO2010115843A3 (en) 2010-12-02
PL3097925T3 (pl) 2020-02-28
JP2012522754A (ja) 2012-09-27
JP5810076B2 (ja) 2015-11-11
SI2413957T1 (sl) 2016-12-30
AU2010233856B2 (en) 2014-04-10
CL2013002888A1 (es) 2014-09-05
HK1231408A1 (en) 2017-12-22
AU2010233856A2 (en) 2011-10-27
HK1164127A1 (en) 2012-09-21
UA107571C2 (xx) 2015-01-26
CL2011002457A1 (es) 2012-03-16
ES2595371T3 (es) 2016-12-29
PL2413957T3 (pl) 2017-01-31
CN102946899A (zh) 2013-02-27
BRPI1015088B1 (pt) 2021-06-29
IL215451A0 (en) 2011-12-29
CA2757345C (en) 2020-04-14
MY171300A (en) 2019-10-07
US20120183599A1 (en) 2012-07-19
CA2757345A1 (en) 2010-10-14
HUE044981T2 (hu) 2019-12-30
NZ595856A (en) 2014-05-30
US20140255412A1 (en) 2014-09-11
EP2413957B1 (en) 2016-07-27
EP3097925B1 (en) 2019-06-12
PT3097925T (pt) 2019-07-23
MA34120B1 (fr) 2013-04-03
IL215451A (en) 2016-05-31
EP3097925A1 (en) 2016-11-30
ECSP11011367A (es) 2012-03-30
KR20150041203A (ko) 2015-04-15
RU2011144307A (ru) 2013-05-10
US20150259406A1 (en) 2015-09-17
HUE030428T2 (en) 2017-05-29
SI3097925T1 (sl) 2019-11-29
KR20120034609A (ko) 2012-04-12
CR20110509A (es) 2012-02-09
DK2413957T3 (da) 2016-10-10
KR101770436B1 (ko) 2017-08-23
CO6390113A2 (es) 2012-02-29
ES2738623T3 (es) 2020-01-24
AU2010233856A1 (en) 2011-10-27
EP2413957A2 (en) 2012-02-08
CN105524160A (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201700008B (it) Composizione farmaceutica
BRPI1012539A2 (pt) composições farmacêuticas
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
BRPI1015939A2 (pt) composição farmacêutica
SMT201600307B (it) Composizione liposomiale
DK3246018T3 (da) Farmaceutisk sammensætning
BRPI1013588A2 (pt) composição
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
EP2451274A4 (en) Pharmaceutical compositions
SMT201400069B (it) Formulazione farmaceutica
BRPI1015474A2 (pt) composição
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
IT1394400B1 (it) Composizioni farmaceutiche
EE201300005A (et) Ravimkoostis
DK2285413T3 (da) Farmaceutisk sammensætning
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0922653A2 (pt) preparação farmacêutica
BRPI1005318A2 (pt) composição
BR112012001340A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica